Computational Development of Novel Dyslipidemia Therapeutic Candidates to Disrupt ApoC-III Conformation

破坏 ApoC-III 构象的新型血脂异常治疗候选物的计算开发

基本信息

  • 批准号:
    10760187
  • 负责人:
  • 金额:
    $ 28.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

Project Abstract Cardiovascular Disease (CVD) is a significant threat in the United States and developing countries across the globe. Widely associated with elevated low density lipoprotein cholesterol (LDL-c), therapeutic interventions are primarily focused on reduction of LDL-c plasma levels. Despite the ability to therapeutically reach these target levels, many patients maintain high cardiovascular risk profiles. A causal contributor to this therapeutic paradox is the development of triglyceride-rich lipoprotein (TRL) particles, highly atherogenic remnant particles that are the result of impaired lipase catabolism. Exhibiting resistance to current FDA approved LDL-c lowering medications, these particles maintain significant cardiovascular risk despite the over lowering of LDL-c. It has been determined that high apolipoprotein C-III (ApoC-III) is a hallmark of TRL particles. The sinister nature of ApoC-III is well established as it possesses key functions that include, but are not limited to; inhibition of Lipoprotein Lipase (LPL), impairment of HDL cholesterol efflux and retardation of lipoprotein particle hepatic uptake. As a potential solution, iMBP is developing new therapeutic compounds that target ApoC-III. Our current research efforts have computationally identified the potential to induce a conformational distortion in the ApoC-III target upon binding. Due to a highly flexible hinge region in the molecule that is necessary for ApoC-III to stabilize on lipoprotein particles, the induction of a conformational change could provide a unique therapeutic mode of action in action for reducing TRL levels. This proof-of-concept work is to computationally reengineer a current proprietary therapeutic candidate to augmented ApoC-III distortion capabilities. An expression library will then be expressed and top candidates will be functionally tested for binding. Split into 2 Specific Aims, the final evaluation of feasibility testing will determine the degree of distortion that is achieved as a consequence of binding. The milestone for this final Aim is the identification of a molecule that binds ApoC-III and creates a measurable change in its conformation exhibited as an increase in the protein’s end to end distance. The satisfaction of this milestone would lead to a SBIR Phase 2 plan that would further evaluate the influence that an artificially induced ApoC-III conformational distortion could play in destabilizing its lipoprotein particle binding characteristics and assist in plasma clearance that would culminate in pre-clinical testing.
项目摘要 心血管疾病(CVD)是美国和发展中国家的重大威胁 遍布地球仪。与低密度脂蛋白胆固醇(LDL-c)升高广泛相关, 治疗干预主要集中在降低LDL-C血浆水平。尽管 尽管有能力在治疗上达到这些目标水平,但许多患者仍维持高心血管风险 数据区.这种治疗悖论的一个因果贡献者是富含甘草酸的药物的发展。 脂蛋白(TRL)颗粒,高度致动脉粥样硬化的残余颗粒,是受损的 脂肪酶催化剂对目前FDA批准的降LDL-c药物表现出耐药性, 尽管LDL-C过度降低,这些颗粒仍保持显著的心血管风险。它有 已经确定高载脂蛋白C-III(ApoC-III)是TRL颗粒的标志。的 ApoC-III的险恶性质是众所周知的,因为它具有关键功能,包括但不限于 不限于:抑制脂蛋白脂酶(LPL),损害HDL胆固醇流出, 脂蛋白颗粒肝摄取延迟。作为一种潜在的解决方案,iMBP正在开发新的 靶向ApoC-III的治疗性化合物。我们目前的研究工作在计算上 鉴定了在结合后诱导ApoC-III靶标构象畸变的潜力。 由于分子中的高度柔性铰链区是ApoC-III稳定在 脂蛋白颗粒,诱导构象变化可以提供一种独特的治疗方法, 降低TRL水平的作用方式。这项概念验证工作是在计算上 重新设计当前的专有候选治疗方法以增强ApoC-III失真 能力的然后将表达表达文库,并且将功能性地表达最佳候选者。 测试绑定。分为2个具体目标,可行性测试的最终评估将决定 由于结合而达到的变形程度。这场决赛的里程碑 目的是鉴定一种结合ApoC-III并在其分子中产生可测量的变化的分子。 构象表现为蛋白质的端到端距离的增加。满意 这一里程碑将导致SBIR第二阶段计划,该计划将进一步评估 人工诱导的ApoC-III构象畸变可能会使其脂蛋白不稳定, 颗粒结合特性,并有助于血浆清除,最终导致临床前 试验.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Urban A Kiernan其他文献

Urban A Kiernan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Urban A Kiernan', 18)}}的其他基金

MS based approaches for diabetes biomarker discovery
基于 MS 的糖尿病生物标志物发现方法
  • 批准号:
    7500061
  • 财政年份:
    2005
  • 资助金额:
    $ 28.31万
  • 项目类别:
MS based approaches for diabetes biomarker discovery
基于 MS 的糖尿病生物标志物发现方法
  • 批准号:
    7617578
  • 财政年份:
    2005
  • 资助金额:
    $ 28.31万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 28.31万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了